Phospholipid metabolism changes in rat tissues in vitro after injections of propranolol

Anuradha Pappu, G. Hauser

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

When added to incubations in vitro, (±)-propranolol, a cationic amphiphilic drug, causes profound alterations in incorporation of [32P]orthosphosphate into rat cerebral cortex phospholipids. These include increases in the labeling of phosphatidic acid and polyphosphoinositides and a decrease in the labeling of phosphatidylcholine. Similar changes occurred in a dose-dependent manner in incubations of cerebral cortex mince, prepared from animals injected i.p. 30 min before death with doses of propranolol ranging from 7.5 to 45 mg/kg. All changes in total incorporation and in labeling pattern had disappeared 3 hr after injection, indicating the reversibility of the effect. Repeated injections of low doses of propranolol (7.5 mg/kg) brought about significant changes in the labeling of brain cortex mince phospholipids, and especially a reduction in total incorporation. Addition of propranolol to kidney and liver minces caused reduction in the labeling of phosphatidylcholine and phosphatidylethanolamine and selective increases in the labeling of acidic lipids, restricted to phosphatidic acid in liver and phosphatidylinositol in kidney. After injection of 45 mg of propranolol per kg, but not at 15 mg/kg, some alterations in the labeling pattern were observed in liver and kidney minces. The differential response of tissues to propranolol injections can be explained on the basis of the pharmacokinetics of drug distribution and clearance and metabolic capacities of the tissues. Changes in phospholipid metabolism may be in part responsible for deleterious side effects that can occur during therapy with high doses of propranolol.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume222
Issue number1
StatePublished - 1982
Externally publishedYes

Fingerprint

Propranolol
Phospholipids
Injections
Phosphatidic Acids
Phosphatidylcholines
Kidney
Cerebral Cortex
Liver
Phosphatidylinositol Phosphates
Phosphatidylinositols
In Vitro Techniques
Pharmaceutical Preparations
Pharmacokinetics
Lipids
Brain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Phospholipid metabolism changes in rat tissues in vitro after injections of propranolol. / Pappu, Anuradha; Hauser, G.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 222, No. 1, 1982, p. 109-115.

Research output: Contribution to journalArticle

@article{040e68dac1ab4709bb0aac4b8b87216e,
title = "Phospholipid metabolism changes in rat tissues in vitro after injections of propranolol",
abstract = "When added to incubations in vitro, (±)-propranolol, a cationic amphiphilic drug, causes profound alterations in incorporation of [32P]orthosphosphate into rat cerebral cortex phospholipids. These include increases in the labeling of phosphatidic acid and polyphosphoinositides and a decrease in the labeling of phosphatidylcholine. Similar changes occurred in a dose-dependent manner in incubations of cerebral cortex mince, prepared from animals injected i.p. 30 min before death with doses of propranolol ranging from 7.5 to 45 mg/kg. All changes in total incorporation and in labeling pattern had disappeared 3 hr after injection, indicating the reversibility of the effect. Repeated injections of low doses of propranolol (7.5 mg/kg) brought about significant changes in the labeling of brain cortex mince phospholipids, and especially a reduction in total incorporation. Addition of propranolol to kidney and liver minces caused reduction in the labeling of phosphatidylcholine and phosphatidylethanolamine and selective increases in the labeling of acidic lipids, restricted to phosphatidic acid in liver and phosphatidylinositol in kidney. After injection of 45 mg of propranolol per kg, but not at 15 mg/kg, some alterations in the labeling pattern were observed in liver and kidney minces. The differential response of tissues to propranolol injections can be explained on the basis of the pharmacokinetics of drug distribution and clearance and metabolic capacities of the tissues. Changes in phospholipid metabolism may be in part responsible for deleterious side effects that can occur during therapy with high doses of propranolol.",
author = "Anuradha Pappu and G. Hauser",
year = "1982",
language = "English (US)",
volume = "222",
pages = "109--115",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Phospholipid metabolism changes in rat tissues in vitro after injections of propranolol

AU - Pappu, Anuradha

AU - Hauser, G.

PY - 1982

Y1 - 1982

N2 - When added to incubations in vitro, (±)-propranolol, a cationic amphiphilic drug, causes profound alterations in incorporation of [32P]orthosphosphate into rat cerebral cortex phospholipids. These include increases in the labeling of phosphatidic acid and polyphosphoinositides and a decrease in the labeling of phosphatidylcholine. Similar changes occurred in a dose-dependent manner in incubations of cerebral cortex mince, prepared from animals injected i.p. 30 min before death with doses of propranolol ranging from 7.5 to 45 mg/kg. All changes in total incorporation and in labeling pattern had disappeared 3 hr after injection, indicating the reversibility of the effect. Repeated injections of low doses of propranolol (7.5 mg/kg) brought about significant changes in the labeling of brain cortex mince phospholipids, and especially a reduction in total incorporation. Addition of propranolol to kidney and liver minces caused reduction in the labeling of phosphatidylcholine and phosphatidylethanolamine and selective increases in the labeling of acidic lipids, restricted to phosphatidic acid in liver and phosphatidylinositol in kidney. After injection of 45 mg of propranolol per kg, but not at 15 mg/kg, some alterations in the labeling pattern were observed in liver and kidney minces. The differential response of tissues to propranolol injections can be explained on the basis of the pharmacokinetics of drug distribution and clearance and metabolic capacities of the tissues. Changes in phospholipid metabolism may be in part responsible for deleterious side effects that can occur during therapy with high doses of propranolol.

AB - When added to incubations in vitro, (±)-propranolol, a cationic amphiphilic drug, causes profound alterations in incorporation of [32P]orthosphosphate into rat cerebral cortex phospholipids. These include increases in the labeling of phosphatidic acid and polyphosphoinositides and a decrease in the labeling of phosphatidylcholine. Similar changes occurred in a dose-dependent manner in incubations of cerebral cortex mince, prepared from animals injected i.p. 30 min before death with doses of propranolol ranging from 7.5 to 45 mg/kg. All changes in total incorporation and in labeling pattern had disappeared 3 hr after injection, indicating the reversibility of the effect. Repeated injections of low doses of propranolol (7.5 mg/kg) brought about significant changes in the labeling of brain cortex mince phospholipids, and especially a reduction in total incorporation. Addition of propranolol to kidney and liver minces caused reduction in the labeling of phosphatidylcholine and phosphatidylethanolamine and selective increases in the labeling of acidic lipids, restricted to phosphatidic acid in liver and phosphatidylinositol in kidney. After injection of 45 mg of propranolol per kg, but not at 15 mg/kg, some alterations in the labeling pattern were observed in liver and kidney minces. The differential response of tissues to propranolol injections can be explained on the basis of the pharmacokinetics of drug distribution and clearance and metabolic capacities of the tissues. Changes in phospholipid metabolism may be in part responsible for deleterious side effects that can occur during therapy with high doses of propranolol.

UR - http://www.scopus.com/inward/record.url?scp=0019955964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019955964&partnerID=8YFLogxK

M3 - Article

VL - 222

SP - 109

EP - 115

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -